Menu Search
Equities

Invitae Corp

0JDB:LSE

Invitae Corp

Actions
  • Price (USD)0.0005
  • Today's Change0.00 / 0.00%
  • Shares traded2.30k
  • 1 Year change-99.95%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 14:50 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

  • Revenue in USD (TTM)481.58m
  • Net income in USD-1.44bn
  • Incorporated2010
  • Employees1.70k
  • Location
    Invitae Corp1400 16Th StreetSAN FRANCISCO 94103United StatesUSA
  • Phone+1 (415) 374-7782
  • Fax+1 (415) 276-4164
  • Websitehttps://www.invitae.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.